pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Company profile
Ticker
PLSE
Exchange
Website
CEO
Darrin R. Uecker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Electroblate, Inc.
SEC CIK
Corporate docs
Subsidiaries
NanoBlate Corp. • BioElectroMed Corp. • Pulse Biosciences BV • 2783162 Ontario Inc. ...
PLSE stock data
Latest filings (excl ownership)
8-K
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
11 Mar 24
8-K
Other Events
14 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
2 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
22 Dec 23
8-K
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
20 Dec 23
DEF 14A
Definitive proxy
27 Nov 23
8-K
Regulation FD Disclosure
27 Nov 23
8-K
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
21 Nov 23
PRE 14A
Preliminary proxy
13 Nov 23
Transcripts
PLSE
Earnings call transcript
2023 Q3
13 Nov 23
PLSE
Earnings call transcript
2023 Q2
10 Aug 23
PLSE
Earnings call transcript
2023 Q1
11 May 23
PLSE
Earnings call transcript
2022 Q4
30 Mar 23
PLSE
Earnings call transcript
2022 Q3
11 Nov 22
PLSE
Earnings call transcript
2022 Q2
10 Aug 22
PLSE
Earnings call transcript
2022 Q1
12 May 22
PLSE
Earnings call transcript
2021 Q4
1 Apr 22
PLSE
Earnings call transcript
2021 Q3
16 Nov 21
PLSE
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.39 mm | 50.39 mm | 50.39 mm | 50.39 mm | 50.39 mm | 50.39 mm |
Cash burn (monthly) | 2.79 mm | 1.56 mm | 3.75 mm | 3.37 mm | 3.50 mm | 2.85 mm |
Cash used (since last report) | 16.63 mm | 9.34 mm | 22.38 mm | 20.13 mm | 20.86 mm | 17.02 mm |
Cash remaining | 33.75 mm | 41.05 mm | 28.00 mm | 30.26 mm | 29.53 mm | 33.37 mm |
Runway (months of cash) | 12.1 | 26.2 | 7.5 | 9.0 | 8.4 | 11.7 |
Institutional ownership, Q3 2023
7.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 17 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 15.23 bn |
Total shares | 4.36 mm |
Total puts | 1.20 k |
Total calls | 187.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 966.43 k | $3.89 bn |
BAC Bank Of America | 791.97 k | $3.19 bn |
Duggan Robert W | 492.07 k | $3.96 mm |
Geode Capital Management | 354.09 k | $1.43 bn |
Vanguard | 341.47 k | $1.38 bn |
STT State Street | 284.24 k | $1.15 bn |
Griffin Asset Management | 274.76 k | $1.11 bn |
NTRS Northern Trust | 178.79 k | $720.52 mm |
Spotlight Asset | 72.09 k | $290.52 mm |
Renaissance Technologies | 71.50 k | $288.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Dec 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 9.15 | 17,999 | 164.69 k | 36,984,179 |
11 Dec 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 9.36 | 90,118 | 843.50 k | 36,966,180 |
8 Dec 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 9.54 | 116,656 | 1.11 mm | 36,876,062 |
7 Dec 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 9.19 | 74,852 | 687.89 k | 36,759,406 |
6 Dec 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 9.06 | 82,813 | 750.29 k | 36,684,554 |
6 Dec 23 | Duggan Robert W | Common Stock | Option exercise | Acquire M | No | No | 5.95 | 9,933 | 59.10 k | 36,601,741 |
6 Dec 23 | Duggan Robert W | Stock Option Common Stock | Option exercise | Dispose M | No | No | 5.95 | 9,933 | 59.10 k | 0 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
28 Mar 24
Pulse Biosciences Q4 EPS $(0.22) Up From $(0.25) YoY
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
Pulse Biosciences Announces FDA 5 Clearance For Cellfx NSPFA Percutaneous Electrode System
8 Mar 24
Press releases
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
8 Mar 24
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
14 Feb 24
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
31 Jan 24
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
2 Jan 24